Mosaic for Mental Health art gallery returns for 28th year in Dartmouth, N.S. - CTV News

Nova ScotiaStephanie Comeau says her family doctor told her he couldn't remove the birth control device. She said after he tried referrals to three gynecologists without success, he asked her to try a sexual health clinic. Comeau says it's disheartening there is seemingly little training on women's health.'If you're not advocating for yourself, you're going to suffer in silence,' says Stephanie ComeauAnjuli Patil · CBC News · Posted: Oct 04, 2026 5:00 AM EDT | Last Updated: October 4Listen to this articleEstimated 4 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Stephanie Comeau said she has been trying to get the T-shaped birth control device removed since June. (Ben Nelms/CBC)A Dartmouth, N. S., woman says there is seemingly little research and training on women's health after she learned her family doctor couldn't remove her IUD.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.